

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sirnaomics Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2257)

**CHANGE OF CHIEF EXECUTIVE OFFICER
AND
RE-DESIGNATION OF DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sirnaomics Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that, with effect from November 5, 2024, (i) Dr. Poon Hung Fai (“**Dr. Poon**”) has been appointed as the Chief Executive Officer of the Group and Dr. Yang Lu (*alias* Patrick Lu) (“**Dr. Lu**”), the former Chief Executive Officer of the Group, has been re-designated as the Chief Scientific Officer of the Group, and will provide support to Dr. Poon and facilitate a smooth transition; and (ii) Dr. Lu has been re-designated from an executive Director to a non-executive Director. Dr. Lu shall remain as the Chairman of the Board, the President and a member of the nomination committee of the Board.

The biographical details of Dr. Poon are set out as follows:

Dr. Poon, aged 46, is an executive Director and the Chief Executive Officer of the Group. He has more than 19 years of experience in the biotechnology sector. He founded QuaCell Biotechnology Co., Ltd. (“**QuaCell**”), a company primarily engaged in the research and manufacturing of core materials for biopharmaceutical production, in April 2018 and served as its general manager until April 2024. QuaCell was acquired by Shanghai LePure Biotech Co., Ltd. (“**LePure Biotech**”), a company primarily engaged in the research and development and the production of single-use equipment and consumables, in January 2023, and Dr. Poon currently serves as the chief strategy officer of LePure Biotech since January 2023. Dr. Poon also served as (i) the chief scientific officer of Hisun Pharmaceutical (Hangzhou) Co., Ltd., the then subsidiary and currently an investee company of Zhejiang Hisun Pharmaceutical Co., Ltd. listed on the Shanghai Stock Exchange (stock code: 600267), from June 2017 to November 2017, and as the R&D director of cell culture from September 2012 to June 2017; and (ii) a senior scientist of Sigma-Aldrich Fine Chemicals (currently a subsidiary of Merck KGaA, a science and technology company listed on the Frankfurt Stock Exchange (stock code: MRK)) from December 2007 to August 2012.

Dr. Poon received his bachelor's degree of science in chemistry from the University of Kentucky in the U.S. in May 2001, and a doctoral degree in biological/analytical chemistry from the same university in December 2005. Dr. Poon also received a master of business administration degree from the University of South Florida in the U.S. in December 2010.

As at the date of this announcement, Dr. Poon was deemed to be interested in an aggregate of 17,527,696 shares of the Company (the "**Shares**") and underlying Shares, within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**").

Dr. Poon is entitled to remuneration in accordance with the remuneration policies determined by the remuneration committee of the Board (the "**Remuneration Committee**") from time to time and, as at the date of this announcement, Dr. Poon is entitled to nil annual emolument.

Save as disclosed above, as at the date of this announcement, Dr. Poon confirmed that (i) he has not held any directorship in other public listed companies in Hong Kong or overseas in the past three years; (ii) he does not hold any other position with the Company or any members of the Group; (iii) he does not have any other major appointments and professional qualifications; (iv) he does not have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (v) he does not hold any other interests in the Shares within the meaning of Part XV of the SFO.

Save as disclosed above, the Board is not aware of any other matter in relation to the appointment of Dr. Poon that needs to be brought to the attention of the shareholders of the Company and there is no other information relating to Dr. Poon which is required to be disclosed pursuant to any of the requirements of Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

The biographical details of Dr. Lu are set out as follows:

Dr. Lu, aged 69, is the founder, the Chairman of the Board, a non-executive Director, the President and the Chief Scientific Officer of the Group. Dr. Lu has led the Company from an early discovery effort to an siRNA therapeutics product company, with multiple programs currently at different clinical stages. Dr. Lu is a member of the nomination committee of the Board and also a director of certain subsidiaries of the Company.

Prior to establishing the Group, Dr. Lu served as a lab head and senior scientist at Genetic Therapy, Inc., a Novartis company in the U.S. from April 1994 to April 2000, and worked at Digene Corporation in the U.S. from May 2000 to May 2001. In June 2001, Dr. Lu co-founded Intradigm Corp. in the U.S. and served as the executive vice president and led research and development until January 2007.

Historically, Dr. Lu had also served as a senior scientific advisor for the South China Biotechnology Center, Sun Yat-sen University in Guangzhou in 1998, an adjunct professor (Industry) of Nanjing University from September 2009 to September 2012, the member of the task force to study nanobiotechnology by the governor of State of Maryland in the U.S. in 2010, and an adjunct professor of the South China Science and Technology University from December 2012 to November 2014. Dr. Lu has authored and co-authored more than 60 scientific publications, including a senior author for a research article on RNAi therapeutics in “Nature Medicine” in September 2005 and is the inventor and/or co-inventor of more than 200 patents.

Dr. Lu obtained a bachelor’s degree in biology, a master’s degree and a doctoral degree in botany from Sun Yat-sen University (中山大學) in the PRC in January 1982, December 1984 and June 1987, respectively. He also conducted postdoctoral research in molecular genetics at the University of Maryland at College Park in the U.S. from December 1987 to April 1990, where he was awarded a National Science Foundation Postdoctoral Fellowship Grant, and postdoctoral research in cancer from April 1990 to March 1992, as well as a research faculty from April 1992 to April 1993 at Georgetown University Medical Center in the U.S. where he was awarded a Junior Faculty Grant from American Cancer Society in 1992. Dr. Lu started his biotech industry career at Microbiological Associates Inc. (currently BioReliance Corporation), from April 1993 to April 1994 as a scientist.

As at the date of this announcement, Dr. Lu was deemed to be interested in an aggregate of 11,496,232 Shares and underlying Shares, within the meaning of Part XV of the SFO.

Dr. Lu is entitled to remuneration in accordance with the remuneration policies determined by the Remuneration Committee from time to time and, as at the date of this announcement, Dr. Lu is entitled to an annual cash compensation of US\$170,000.

Save as disclosed above, as at the date of this announcement, Dr. Lu confirmed that (i) he has not held any directorship in other public listed companies in Hong Kong or overseas in the past three years; (ii) he does not hold any other position with the Company or any members of the Group; (iii) he does not have any other major appointments and professional qualifications; (iv) he does not have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (v) he does not hold any other interests in the Shares within the meaning of Part XV of the SFO.

Save as disclosed above, the Board is not aware of any other matter in relation to the re-designations of Dr. Lu that needs to be brought to the attention of the shareholders of the Company and there is no other information relating to Dr. Lu which is required to be disclosed pursuant to any of the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express its sincere gratitude to Dr. Lu for his valuable contribution to the Group during his tenure in office as the Chief Executive Officer of the Group, and would like to extend its warmest welcome to Dr. Poon on his new appointment.

By order of the Board
Sirnaomics Ltd.
Yang (Patrick) Lu
Chairman and Non-Executive Director

Hong Kong, November 6, 2024

As at the date of this announcement, the Board comprises Dr. Poon Hung Fai as executive Director, Dr. Yang Lu (alias Patrick Lu), Mr. Mincong Huang and Mr. Jiankang Zhang as non-executive Directors, and Dr. Cheung Hoi Yu, Ms. Monin Ung and Ms. Shing Mo Han, Yvonne (alias Mrs. Yvonne Law) as independent non-executive Directors.